PRIMO 2017 – Day Two Recap and Highlights

Rain showers rolled through, but the discussion was bright inside the general session room on day two of the 2nd Annual Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Meeting.

The second day of sessions kicked off with the presentation of the 2017 Women in Oncology Awards – awards given to women in the areas of academia, advocacy, and industry for their exception contributions to oncology. This year’s winners are: academia – Dr. Nancy Davidson, Executive Director of the Fred Hutchinson and University of Washington Cancer Consortium; advocacy – Kathy Giusti, Founder and Executive Chairman of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC); and industry – Jill DeSimone, Head of US Oncology at Merck. Ms. DeSimone was in attendance, and delivered a powerful thank you speech, helping set the tone for the day.

Co-chair Dr. Julie Vose then initiated the hematologic malignancies session, which also saw a talk from PRIMO Steering Committee Member Dr. Sagar Lonial, Emory University School of Medicine. This session saw presentations covering topics such as advancements in personalized treatment of lymphomas and multiple myeloma, as well as emerging therapeutic strategies for AML and MDS. The session faculty then took the stage for a long panel discussion, fielding numerous questions from an inquisitive audience.

The faculty-attendee engagement continued into the afternoon session dedicated to genitourinary malignancies, which was headlined by Dr. Ravi Madan of the NCI – Dr. Madan presented on three occasions during the session, and received an abundant amount of questions during the afternoon panel, going so far to continue answering questions well after the conclusion of day two’s sessions.


Day Two Highlights

From Dr. Julie Vose’s presentation, “Advances in Personalized Treatment of Hodgkin and Non-Hodgkin Lymphoma”:

  • The ZUMA-1 CAR-T Cell trial saw a complete response rate 6 times higher than historical outcomes, with a 39% durable complete response at 3 months in patients with patients with refractory diffuse large b-cell lymphoma.

From Dr. Lonial’s talk, “Evidence Based Approaches for Induction Therapy”:

  • IMID/PI is the standard of care for newly diagnosed Multiple Myeloma patients, except for frail patients, but it’s important to remember maintenance of these patients is not “one size fits all.”

From Dr. Madan’s presentation, “Bladder Cancer: Opportunites and Innovations With Immunotherapy”:

  • Immune combinations that optimize in vivo expansion will allow for personalized immune responses against a patient’s own tumor, and evaluating the breadth of the immune response in vivo (antigen cascade) may ultimately be a biomarker that assists in selecting optimal immunotherapeutic regimens.

Leave a Reply

Your email address will not be published. Required fields are marked *